Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide plus cisplatin for newly diagnosed central nervous system malignant germ cell tumors
ChiCTR2500106961Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teniposide and cisplatin in intracranial germ cell tumor (ICGCT), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective remission rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
teniposidecisplatin
03
Conditions
intracranial germ cell tumor (ICGCT)
Beyond the preview
Go deeper on ChiCTR2500106961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106961.